Brown Advisory Inc. Has $70.67 Million Stock Holdings in Phreesia, Inc. $PHR

Brown Advisory Inc. trimmed its stake in shares of Phreesia, Inc. (NYSE:PHR) by 34.1% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 2,482,955 shares of the company’s stock after selling 1,287,525 shares during the quarter. Brown Advisory Inc. owned about 4.17% of Phreesia worth $70,665,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Phreesia by 108.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,644,988 shares of the company’s stock valued at $67,606,000 after purchasing an additional 1,377,904 shares in the last quarter. Loomis Sayles & Co. L P acquired a new position in shares of Phreesia in the 2nd quarter valued at approximately $34,162,000. American Century Companies Inc. raised its position in shares of Phreesia by 3,741.9% in the 1st quarter. American Century Companies Inc. now owns 983,440 shares of the company’s stock valued at $25,137,000 after buying an additional 957,842 shares in the last quarter. Nuveen LLC bought a new stake in shares of Phreesia during the 1st quarter worth approximately $14,206,000. Finally, Champlain Investment Partners LLC boosted its position in shares of Phreesia by 20.0% during the 1st quarter. Champlain Investment Partners LLC now owns 2,946,489 shares of the company’s stock worth $75,312,000 after acquiring an additional 490,340 shares in the last quarter. Institutional investors own 92.10% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have commented on PHR. Mizuho assumed coverage on shares of Phreesia in a research report on Wednesday, August 27th. They set an “outperform” rating and a $36.00 price objective for the company. Truist Financial boosted their price target on Phreesia from $35.00 to $36.00 and gave the stock a “buy” rating in a report on Friday, September 5th. Raymond James Financial set a $33.00 price objective on Phreesia and gave the company an “outperform” rating in a research note on Friday, September 5th. Piper Sandler lifted their target price on Phreesia from $33.00 to $34.00 and gave the company an “overweight” rating in a research report on Friday, September 5th. Finally, Canaccord Genuity Group increased their target price on shares of Phreesia from $34.00 to $38.00 and gave the stock a “buy” rating in a report on Friday, September 5th. Fourteen equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $33.86.

Phreesia Price Performance

Shares of PHR opened at $20.26 on Friday. The company has a quick ratio of 2.12, a current ratio of 2.12 and a debt-to-equity ratio of 0.02. The stock has a market cap of $1.21 billion, a PE ratio of -48.24 and a beta of 0.64. Phreesia, Inc. has a 12-month low of $18.55 and a 12-month high of $32.76. The business has a 50-day simple moving average of $22.09 and a two-hundred day simple moving average of $25.27.

Phreesia (NYSE:PHR) last announced its quarterly earnings results on Thursday, September 4th. The company reported $0.01 EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.08. Phreesia had a negative return on equity of 8.75% and a negative net margin of 5.35%.The firm had revenue of $117.26 million for the quarter, compared to analyst estimates of $116.39 million. During the same period last year, the firm posted ($0.03) earnings per share. The business’s revenue for the quarter was up 14.9% on a year-over-year basis. Analysts anticipate that Phreesia, Inc. will post -1.1 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, General Counsel Allison C. Hoffman sold 3,133 shares of Phreesia stock in a transaction that occurred on Tuesday, September 16th. The shares were sold at an average price of $23.28, for a total transaction of $72,936.24. Following the sale, the general counsel directly owned 139,037 shares in the company, valued at $3,236,781.36. This trade represents a 2.20% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider David Linetsky sold 2,165 shares of the company’s stock in a transaction that occurred on Tuesday, September 16th. The shares were sold at an average price of $23.28, for a total transaction of $50,401.20. Following the completion of the transaction, the insider owned 174,952 shares of the company’s stock, valued at approximately $4,072,882.56. This trade represents a 1.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 26,174 shares of company stock worth $603,835 over the last quarter. 5.50% of the stock is currently owned by corporate insiders.

Phreesia Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.